Discovery Laboratorie Kauf zu 2,30 $ Ziel 2,55 €

BMO liegt hier ca 25 % im Minus....auf ein Rebound mit ca 10 % zu spekulieren sollte jetzt verkehrt sein.....Nachkauf bei weiterer schwäche nicht ausgeschlossen.



Jäger u Sammler

Sorry für die Fehler im Text meinte 2,55 $ und nicht € und ,,zu spekulieren sollte jetzt NICHT verkehrt sein,,....


Jäger u Sammler

Saubere 8 % in 24 Std was will man mehr..?

Oder doch lieber 2 Jahre Tagesgeldkonto mit 4 % Verzinsung... :-)?


Nein danke !!!



Jäger u Sammler

Kann man jetzt Kaufen ! Stoplos..2,25 $



,,Man hat nicht Recht, weil der Markt rauf oder runter geht,  
      sondern weil man die besseren Argumente hat.,,

Hab mir heute auch einige Aktien gekauft.
Hoffe aber auf höhere Gewinne um die 3$;-)



**************************************************
Wer keine Angst vor dem Teufel hat , Braucht auch keinen Gott!!
**************************************************

Discovery Labs Announces Resignation of CEO Robert J. Capetola, Ph.D.; W. Thomas Amick, Chairman of the Board, Appointed Interim CEO

www.globenewswire.com/newsroom/...ml?ref=rss&&d=171451

WARRINGTON, Pa. (AP) -- Biotechnology company Discovery Laboratories Inc. said Thursday that Robert Capetola has resigned as CEO, president and a director, and Chairman W. Thomas Amick will take on the role of interim CEO.

Capetola had served as Discovery Labs' CEO since the company's founding in 1996.

In a statement, the company said that Capetola and the board of directors felt that "a transition in leadership at this time is appropriate for Discovery Labs to capitalize on its strategic endeavors."

The company said it wants to find partners and capital to help build its pipeline of treatments for respiratory distress syndrome in infants.

Amick, who has been chairman since March 2007, will serve as CEO until the company secures "appropriate strategic alliances and necessary capital" and begins the search for a permanent chief.

The company's Surfaxin drug candidate, aimed at treating respiratory distress syndrome in infants, has faced long delays in approvals from the Food and Drug Administration. It had once hoped for a drug approval by April 2006.

finance.yahoo.com/news/...-CEO-resigns-apf-2621322405.html?x=0

ist den heute mit unserer disco los? *g*

of Aerosol Medicine and Pulmonary Drug Delivery

www.globenewswire.com/newsroom/news.html?ref=rss&d=191903

Wird schon werden mit unserem $1 Boogie hier... :-)

Potential Protective Role for Lung Transplantation in Established Preclinical Model

www.globenewswire.com/newsroom/news.html?ref=rss&d=192016

falsche Richtung!!

for lung drug

www.finanznachrichten.de/...quality-test-for-lung-drug-020.htm

www.finanznachrichten.de/...etes-quality-test-for-drug-020.htm

Dann werden wir es erfahren ob es noch weiter hoch oder runter geht.

seekingalpha.com/article/...hospira-javelin-pharma?source=feed

"You know, for as much as I pick on Discovery Laboratories, Inc. (NASDAQ:DSCO), I have to give credit where credit is due. Though under fire, this small cap  has managed to hold the line at the $0.50 cent mark.... a level that's been a key support line since February. Though we saw Discovery Laboratories slip under that line once earlier in the month, it was followed by a quick recovery. It's still a big fat liability, but as long as $0.50 holds up, DSCO owners at least have some sort of anchor for this bearish storm.     "

WARRINGTON, Pa., June 2, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq: DSCO), announced today that The Nasdaq Stock Market, LLC has approved Discovery Labs' application to transfer its stock listing from The NASDAQ Global Market® to The NASDAQ Capital Market®. The transfer will be effective at the opening of the market on June 4, 2010. The Company's common stock will continue to be traded under the symbol "DSCO" and the transfer will have no impact on the ability of investors to trade the stock. The NASDAQ Capital Market is a continuous trading market that operates in the same manner as The NASDAQ Global Market. All companies listed on The NASDAQ Capital Market must meet certain financial requirements and adhere to Nasdaq's corporate governance standards.

www.globenewswire.com/newsroom/news.html?ref=rss&d=193381

translate.google.de/...mp;sl=en&tl=de&hl=&ie=UTF-8